News

Despite showing better composite scores for cognition and ability to perform activities of daily living, a number of the secondary outcomes showed mixed results with the Eli Lilly investigational agent.

Researchers also found that, in comparing ataluren to standard care, ataluren delayed loss in pulmonary function.

The high-dose cohort in part 1 of the FIREFISH study also showed that more than 50% of infants could sit without support and more than 90% could feed orally.

Persons with pediatric-onset MS received higher rates of disability benefits, sickness absence days in their youngest age period, and disability pension days in their oldest age period than those without MS.

The postdoctoral researcher at Columbia University discussed her abstract from ACTRIMS Forum 2021 on the associations of MS diagnosis disclosure and concealment with anxiety and depression.

Here's what is coming soon to NeurologyLive.

In assessing patients treated with siponimod, researchers also saw that plasma neurofilament light levels slightly predicted a reduced risk of disease worsening.

Researchers observed that patients who underwent vagus nerve stimulation reported alertness improvements and most had no major complications.

The director of the Montefiore Headache Center discussed the research he would like to see into the treatment, including the potential of combination approaches.

The partnership is aiming to develop a novel approach to damage repair in multiple sclerosis from a number of potential drug candidates.

Sharon Hesterlee, PhD, executive vice president and chief research officer, MDA, shares an early look at the MDA's 2021 Virtual Clincial and Scientific Conference, March 15-18.

Neurology News Network for the week ending March 13, 2021.

Patients treated with the GammaSense neuromodulation therapeutic also demonstrated a significant 61% reduction in whole brain atrophy and volumetric loss associated with Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 12, 2021.

The senior investigator at the National Institutes of Neurological Disorders and Stroke discussed 2 treatments currently being evaluated for use in multiple sclerosis.

A pair of cerebrovascular and neurosurgery experts discuss a novel approach to communicating hydrocephalus with an arachnoid granulation using a miniature implant, delivered via a percutaneous endovascular catheter.

The executive vice president and chief research officer of the MDA gave an overview of the upcoming virtual annual meeting and her insight on what to look for.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Stewart Factor, DO.

Researchers from Kaohsiung Medical University performed a meta-analysis of 18 RCTs to investigate associations between ASMs and sleep parameters.

The chief diversity, equity and inclusion officer at the Alzheimer’s Association discussed the findings of the association’s special edition of its annual Facts and Figures report.

Researchers found that the proportion of patients meeting DNC criteria suitable for organ donation increased after teleneurology use.

Future analysis evaluating the optimal candidate for disease and duration of treatment for the use of tofacitinib in autoimmune encephalitis is needed, according to the study authors.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed the research opportunities for repurposed anti-inflammatory drugs for Alzheimer disease.

The assistant professor of neurology at Mayo Clinic detailed the areas of autoimmune encephalitis research that need more attention, as well as the diagnostic potential of autoantibody assays.

Garey H. Noritz, MD, walks us through a virtual pediatric neurological exam and notes examination findings that may be identified in an infant with Spinal Muscular Atrophy (SMA).

Diana Castro, MD walks us through a pediatric neurological exam and notes examination findings that may be identified in an infant with Spinal Muscular Atrophy (SMA).

The neurologist from the University of Washington Medical Center discussed how the study of natalizumab adverse events came about and the importance of this monitoring period.

Researchers found that GCIPL thickness, along with disease duration of at least 9 years at baseline, were associated with the highest odds of EDSS worsening.